Core Insights - Teva Pharmaceutical Industries Ltd. has received FDA approval for its biosimilar Ponlimsi, which is a competitor to Amgen's Prolia, aimed at treating various bone conditions [1][8] - The approval is based on evidence demonstrating that Ponlimsi has similar efficacy, safety, and immune response as Prolia [1] - Teva anticipates that the approval will significantly enhance its biosimilar portfolio [3] Product Details - Ponlimsi is approved for all indications of Prolia, including treatment for osteoporosis in high-risk men and postmenopausal women, glucocorticoid-induced osteoporosis, and improving bone mass in certain cancer patients [2] - The biosimilar versions of Prolia and Xgeva were previously approved in the European Union in November 2025, with Prolia generating sales of $4.4 billion in the same year, accounting for 13% of Amgen's total product sales [3][11] Financial Outlook - Teva aims to grow its biosimilars business by $400 million by 2027, with expectations for improvement in its generics business as well [8][13] - The company's global generics business was flat in 2025 compared to 2024, but it is projected to rise in a low single-digit range in 2026 [12][13] Market Performance - Year-to-date, Teva's shares have decreased by 9.2%, while the industry has seen a decline of 8.7% [5]